Condition: Prostate CA · Prostate Cancer (Adenocarcinoma) · Prostate Cancer Surgery · Sponsor: AdventHealth
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in adult males.
This description comes directly from the study's public registry record.
AdventHealth Oncology Research · 407-303-2090 · CFD.ResearchOncology@AdventHealth.com
Always discuss trial participation with your own doctor first.
| AdventHealth Orlando | Orlando, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06631521